Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001683168-25-000267
Filing Date
2025-01-13
Accepted
2025-01-13 08:25:21
Documents
38
Period of Report
2024-11-30

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q FOR NOV 2024 cnbx_i10q-113024.htm   iXBRL 10-Q 285959
2 CERTIFICATION cnbx_ex3101.htm EX-31.1 10444
3 CERTIFICATION cnbx_ex3102.htm EX-31.2 10372
4 CERTIFICATION cnbx_ex3201.htm EX-32.1 4859
5 CERTIFICATION cnbx_ex3202.htm EX-32.2 4637
  Complete submission text file 0001683168-25-000267.txt   1824345

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE cnbx-20241130.xsd EX-101.SCH 15501
7 XBRL CALCULATION FILE cnbx-20241130_cal.xml EX-101.CAL 22755
8 XBRL DEFINITION FILE cnbx-20241130_def.xml EX-101.DEF 37588
9 XBRL LABEL FILE cnbx-20241130_lab.xml EX-101.LAB 171984
10 XBRL PRESENTATION FILE cnbx-20241130_pre.xml EX-101.PRE 131713
41 EXTRACTED XBRL INSTANCE DOCUMENT cnbx_i10q-113024_htm.xml XML 123620
Mailing Address #3 BETHESDA METRO CENTER SUITE 700 BETHESDA MD 20814
Business Address #3 BETHESDA METRO CENTER SUITE 700 BETHESDA MD 20814 877-424-2429
CNBX Pharmaceuticals Inc. (Filer) CIK: 0001343009 (see all company filings)

EIN.: 203373669 | State of Incorp.: NV | Fiscal Year End: 0831
Type: 10-Q | Act: 34 | File No.: 000-52403 | Film No.: 25524956
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)